Coherus Oncology develops and sells LOQTORZI, a cancer medicine, and is developing two other cancer treatment candidates in clinical studies. CHRS reports earnings on Mon, Nov 9, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 29 | HC Wainwright & Co. | Assumed coverage | Buy | |
| Aug 7 | Guggenheim | Maintained | Buy | |
| May 11 | Guggenheim | Initiated | Buy |
Seasonality
How CHRS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
Whale Options Flow
90DNo whale options trades in CHRS in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CHRS is in one of them and how their past CHRS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CHRS in an article yet. Here's the latest on the wider market.
About Coherus Oncology
Coherus Oncology is a cancer drug company based in Redwood City, California. Its main product is LOQTORZI, an antibody medicine that blocks the PD-1 pathway. It is approved in the United States for nasopharyngeal carcinoma, a cancer of the upper throat, and the company sells it for treating cancer patients. The company is also developing two other cancer treatment candidates in clinical studies, aimed at cancers such as liver, head and neck, and colorectal cancer.
- Headquarters
- Redwood City, CA
- Founded
- 2010
- Website
- coherus.com ↗